Obesity Clinical Trial
Official title:
Effects of Intermittent Caloric Restriction in Youth With Cardiometabolic Risk: a Randomized Controlled Pilot Study
Verified date | March 2022 |
Source | Children's Hospital of Fudan University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a randomized controlled pilot study to evaluate the effects of intermittent caloric restriction compared with low carbohydrate diet in youth with cardiometabolic risk.
Status | Completed |
Enrollment | 34 |
Est. completion date | December 1, 2021 |
Est. primary completion date | November 16, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 9 Years to 30 Years |
Eligibility | Inclusion Criteria: Have at least one of the following cardiometabolic abnormalities: 1. Overweight or obesity (central obesity or general obesity) 2. Prediabetes: impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT) 3. Dyslipidemia 4. Elevated blood pressure Criteria for cardiometabolic abnormalities: 1. Overweight or obesity For subjects (9 = age = 18 years) : • General obesity: Body mass index higher than the 85th percentile for overweight and the 90th percentile for obesity, based on the references for screening overweight and obesity in Chinese children and adolescents. • Central obesity: Waist circumference higher than the 90th percentile of the age and gender-specific reference for screening cardiovascular risk factors in Chinese children and adolescents. For subjects ( 19 = age = 30 years) : • General obesity: Body mass index between 24.0 and 27.9 kg/m2 for overweight and =28 kg/m2 for obesity. • Central obesity: Waist circumference =85cm for men and =80cm for female. Based on recommendation of overweight and obesity in Chinese adults. 2. Prediabetes: With IFG and/or IGT. IFG: fasting glucose from 5.6 to 6.9 mmol/L; IGT: 2-h glucose in the 75g oral glucose tolerance test from 7.8 to 11.0 mmol/L. Based on recommendation of American Diabetes Association. 3. Dyslipidemia: For subjects (9 = age = 18 years) : Triglycerides of =1.70 mmol/L or total cholesterol of =5.18 mmol/L or lowdensity lipoprotein cholesterol =3.37 mmol/L or highdensity lipoprotein cholesterol of =1.04 mmol/L. Based on recommendation in Chinese children and adolescents. For subjects ( 19 = age = 30 years) : Triglycerides of =1.7 mmol/L or total cholesterol of =5.2 mmol/L or lowdensity lipoprotein cholesterol =3.4 mmol/L or highdensity lipoprotein cholesterol of =1.0 mmol/L. Based on guideline for the management of dyslipidemia in Chinese adults. 4. Elevated blood pressure: For subjects (9 = age = 18 years) : Blood pressure higher than the 90th percentile of blood pressure age and gender-specific reference standards for Chinese children and adolescents, or blood pressure >120/80 mmHg. For subjects ( 19 = age = 30 years) : Systolic blood pressure=120 mmHg and/or diastolic blood pressure =80 mmHg. Based on Chinese guidelines for the management of hypertension. Exclusion Criteria: 1. Diagnosis of severe diseases such as cardiac insufficiency, severe malnutrition or immunodeficiency. 2. History of bariatric surgery. 3. Use of antiobesity drugs or supplements. |
Country | Name | City | State |
---|---|---|---|
China | Children's Hospital of Fudan University | Shanghai |
Lead Sponsor | Collaborator |
---|---|
Children's Hospital of Fudan University |
China,
Arnason TG, Bowen MW, Mansell KD. Effects of intermittent fasting on health markers in those with type 2 diabetes: A pilot study. World J Diabetes. 2017 Apr 15;8(4):154-164. doi: 10.4239/wjd.v8.i4.154. — View Citation
Harvie MN, Pegington M, Mattson MP, Frystyk J, Dillon B, Evans G, Cuzick J, Jebb SA, Martin B, Cutler RG, Son TG, Maudsley S, Carlson OD, Egan JM, Flyvbjerg A, Howell A. The effects of intermittent or continuous energy restriction on weight loss and metabolic disease risk markers: a randomized trial in young overweight women. Int J Obes (Lond). 2011 May;35(5):714-27. doi: 10.1038/ijo.2010.171. Epub 2010 Oct 5. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Reversal of cardiometabolic abnormalities | The primary outcome is a composite outcome that will be measured by combining multiple reverse outcomes of the following cardiometabolic abnormalities: (1) overweight or obesity, (2) prediabetes, (3) hyperlipidemia and (4) elevated blood pressure. It is defined as occurring if any cardiometabolic abnormality has a reversal outcome at the 14th day of dietary intervention phase.
Reversal of cardiometabolic abnormalities is defined as: At the 14th day of dietary intervention phase, at least one of the following indicators changed from abnormal at baseline to normal: overweight, obesity, prediabetes, hyperlipidemia and elevated blood pressure. (The reversal of overweight or obesity is defined according to reference[1, 2]: For subject with general obesity at baseline: weight loss of 1.5 kg after intervention; For subject with central obesity at baseline: waist circumference reduction of 1.5 cm after intervention.) |
From the baseline (the first day of the intervention phase) to the 14th day of the intervention phase. | |
Secondary | Change in insulin | Serum from fasting blood sample is used for measurement of insulin. | From the baseline (the first day of the intervention phase) to the 14th day of the intervention phase. | |
Secondary | Change in insulin-like growth factor-1 | Fasting blood sample for measurement of insulin-like growth factor-1. | From the baseline (the first day of the intervention phase) to the 14th day of the intervention phase. | |
Secondary | Change in mean blood glucose | Measured by a blood glucose monitor for 24-hour glucose monitoring during the 14-day intervention phase. | From the baseline (the first day of the intervention phase) to the 14th day of the intervention phase. | |
Secondary | Change in gut microbial compositions | Stool sample of subject is used for measurement of gut microbial compositions. | From the baseline (the first day of the intervention phase) to the 14th day of the intervention phase. | |
Secondary | Change in body weight | Body weight is measured according to the Physical Fitness and Health Surveillance of Chinese School Students by trained, certified study staff. It is measured to the nearest 0.1 kg. | From the baseline (the first day of the intervention phase) to the 14th day of the intervention phase. | |
Secondary | Change in body weight | Body weight is measured by subject and reported by electronic questionnaire. It is measured to the nearest 0.1 kg. | From the baseline (the first day of the intervention phase) to the 14th day of the self-maintenance phase. | |
Secondary | Change in waist circumference | Waist circumference is measured to the nearest 0.1 cm using a constant tension tape around the waist at 1 cm below the navel as the subject exhaled. It is calculated as the average value of two measurements. | From the baseline (the first day of the intervention phase) to the 14th day of the intervention phase. | |
Secondary | Change in waist circumference | Waist circumference is measured by subject and reported by electronic questionnaire. It is measured to the nearest 0.1 cm using a constant tension tape around the waist at 1 cm below the navel as the subject exhaled. It is calculated as the average value of two measurements. | From the baseline (the first day of the intervention phase) to the 14th day of the self-maintenance phase. | |
Secondary | Dietary energy intake | Daily dietary energy intake (kcals/day) is calculated by researchers using food weighing photos of the subject. | From the baseline (the first day of the intervention phase) to the 14th day of the intervention phase. | |
Secondary | Self-reported dietary adherence | Adherence to diet will be assessed with a electronic questionnaire in the self-maintenance phase. | At the 14th day of the self-maintenance phase. | |
Secondary | Change in monocyte chemoattractant protein-1 (MCP-1) | MCP-1 will be measured by enzyme-linked immunosorbent assays (R&D Systems, Inc. USA), using fasting serum samples at baseline and 14 days after intervention. | From the baseline (the first day of the intervention phase) to the 14th day of the intervention phase. | |
Secondary | Change in free fatty acid (FFA) | FFA will be measured by enzyme-linked immunosorbent assays (R&D Systems, Inc. USA), using fasting serum samples at baseline and 14 days after intervention. | From the baseline (the first day of the intervention phase) to the 14th day of the intervention phase. | |
Secondary | Change in fibroblast growth factor 21 (FGF-21) | FGF-21 will be measured by enzyme-linked immunosorbent assays (R&D Systems, Inc. USA), using fasting serum samples at baseline and 14 days after intervention. | From the baseline (the first day of the intervention phase) to the 14th day of the intervention phase. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |